Asia Pacific Diltiazem Market

Market Introduction

Diltiazem is a benzothiazepine derivative that acts as an antihypertensive and vasodilator. Diltiazem is an antihypertensive and vasodilator that lowers blood pressure by relaxing the vascular muscle. This is due to the long-term therapeutic effects of decreasing blood pressure since it lowers the risk of fatal and non-fatal cardiovascular events, such as strokes and myocardial infarction. According to in vitro binding experiments, diltiazem is 70%-80% bound to plasma proteins. At clinically relevant concentrations, around 40% of the medication is thought to attach to alpha-1-glycoprotein, whereas about 30% of the drug is thought to bind to albumin.

Market Overview and Dynamics

The Asia Pacific diltiazem market is expected to reach US$ 160.34 million by 2028 from US$ 67.84 million in 2021; it is estimated to grow at a CAGR of 13.1% from 2021 to 2028. Rise in government initiatives for promotion, increase in the prevalence of cardiovascular diseases (CVDs), and rise in the elderly population with heart diseases worldwide are expected to boost the market growth over the years. However, the side effects of Diltiazem on consumption are likely to impact the market's growth in the coming years negatively.

The prevalence of cardiovascular conditions is rising across the world, especially in developing nations. In these nations, the modernized facilities reduced the physical activities of people. Also, the stress level among people is growing. The incidence of CVDs is rising in developing countries, owing to the shift in lifestyle and the other health conditions caused due to the adoption of modernized facilities, which is propelling the demand for Diltiazem. The developing nations are significantly developing their healthcare facilities and services and are heading toward technological advancements. For instance, the structural heart is at the initial stage of development in the regions such as Asia Pacific. In March 2021, Glenmark Pharma gained the final USFDA nod on diltiazem hydrochloride capsules. Glenmark Pharmaceuticals has been granted a competitive generic therapy (CGT) designation for Diltiazem Hydrochloride Extended?Release Capsules USP, 60 mg, 90 mg, and 120 mg. With the approval, the company has become the first approved applicant for such competitive generic therapy and is eligible for 180 days of CGT exclusivity upon commercial marketing. Also, Glenmark is expanding its footprint in Switzerland and other developing countries. Thus, the opportunities for the market players to enter the market with cost-effective products are higher. Therefore, the factors mentioned above would create lucrative opportunities for the growth of the diltiazem market during the forecast period. Also, the diltiazem market is characterized by various small and big companies across Asia Pacific. The market players adopt strategies such as new product launches, regional expansions, and product approvals to increase their market share. The players are investing in R&D to develop advanced technologies and gain significant revenue share. Thus, recent developments are expected to act as a future trend in the diltiazem market.

COVID-19 pandemic has broadly affected economies in the Asia Pacific region. The pandemic has affected three main aspects of the global economy – production, supply chain, and firms and financial markets. The supply chain disruptions and the massive demand for efficient treatments for the therapy of COVID-19 have put the healthcare research industry in a crucial situation in the Asia Pacific region. Prohibitive measures have been taken to control the spread of this pandemic. Recently, patients with both hypertension and obesity have been increasing in Japan at exceptionally high risk of COVID-19, and thus, they need careful observation and intensive treatment. However, it is essential to note that the therapeutic mechanism of calcium channel blockers against COVID-19 still awaits further investigation and randomized controlled clinical trials. This scenario is positively impacting the diltiazem market in Asia Pacific.

Key Market Segments

Based on product, the Asia Pacific diltiazem market is segmented into capsules, injection, and tablets. In 2021, the tablets segment held the largest share of the market. However, the capsules segment is expected to witness the fastest CAGR from 2021 to 2028.

Based on application, the Asia Pacific diltiazem market was segmented into angina, hypertension, and others. In 2021, the hypertension segment held the largest share of the market. The angina segment is expected to grow at the fastest CAGR in the coming years.

Major Sources and Companies Listed

A few of the primary and secondary sources associated with this report on the Asia Pacific diltiazem market are the National Center for Biotechnology Information (NCBI), The China National Committee on Aging (CNCA), and All-India Institute of Medical Sciences (AIIMS), among others.

Reasons to buy the report

• Determine prospective investment areas based on a detailed trend analysis of Asia Pacific diltiazem market over the next years.
• Gain an in-depth understanding of the underlying factors driving demand for different addictions therapeutics segments in the top spending countries and identify the opportunities offered by each of them.
• Strengthen your knowledge of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
• Identify the major channels driving the Asia Pacific diltiazem market, providing a clear picture of future opportunities that will help analyze, resulting in revenue expansion.
• Channelize resources by focusing on the ongoing programs undertaken by the different countries within the Asia Pacific diltiazem market.

ASIA PACIFIC DILTIAZEM MARKET SEGMENTATION

By Product Type

• Tablet
• Capsules
• Injection

By Application

• Hypertension
• Angina
• Others

By Country

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Company Profiles

• Bausch Health Companies Inc.
• Teva Pharmaceutical Industries Ltd
• MYLAN N.V.
• Pfizer Inc.
• Sandoz (Novartis AG)
• Sun Pharmaceutical Industries Ltd
• Hikma Pharmaceuticals PLC
• Zydus Cadila
• Glenmark

Asia Pacific Diltiazem Market Strategic Insights

Asia Pacific DiltiazemMarket Report Highlights

Asia Pacific Diltiazem Market Country and Regional Insights